Literature DB >> 27837027

Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.

Ludmila Danilova1,2,3, Hao Wang1, Joel Sunshine4, Genevieve J Kaunitz4, Tricia R Cottrell5, Haiying Xu4, Jessica Esandrio4, Robert A Anders1,3,5, Leslie Cope1,3, Drew M Pardoll1,3, Charles G Drake1,3,6, Janis M Taube7,3,4,5.   

Abstract

Programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockade has led to remarkable and durable objective responses in a number of different tumor types. A better understanding of factors associated with the PD-1/PD-L axis expression is desirable, as it informs their potential role as prognostic and predictive biomarkers and may suggest rational treatment combinations. In the current study, we analyzed PD-L1, PD-L2, PD-1, and cytolytic activity (CYT) expression, as well as mutational density from melanoma and eight other solid tumor types using The Cancer Genome Atlas database. We found that in some tumor types, PD-L2 expression is more closely linked to Th1/IFNG expression and PD-1 and CD8 signaling than PD-L1 In contrast, mutational load was not correlated with a Th1/IFNG gene signature in any tumor type. PD-L1, PD-L2, PD-1, CYT expression, and mutational density are all positive prognostic features in melanoma, and conditional inference modeling revealed PD-1/CYT expression (i.e., an inflamed tumor microenvironment) as the most impactful feature, followed by mutational density. This study elucidates the highly interdependent nature of these parameters, and also indicates that future biomarkers for anti-PD-1/PD-L1 will benefit from tumor-type-specific, integrated, mRNA, protein, and genomic approaches.

Entities:  

Keywords:  PD-1; PD-L1; PD-L2; melanoma; mutational load

Mesh:

Substances:

Year:  2016        PMID: 27837027      PMCID: PMC5137776          DOI: 10.1073/pnas.1607836113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  88 in total

1.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

2.  TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.

Authors:  Joe-Marc Chauvin; Ornella Pagliano; Julien Fourcade; Zhaojun Sun; Hong Wang; Cindy Sander; John M Kirkwood; Tseng-hui Timothy Chen; Mark Maurer; Alan J Korman; Hassane M Zarour
Journal:  J Clin Invest       Date:  2015-04-13       Impact factor: 14.808

3.  PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

Authors:  Wendy A Cooper; Thang Tran; Ricardo E Vilain; Jason Madore; Christina I Selinger; Maija Kohonen-Corish; PoYee Yip; Bing Yu; Sandra A O'Toole; Brian C McCaughan; Jennifer H Yearley; Lisa G Horvath; Steven Kao; Michael Boyer; Richard A Scolyer
Journal:  Lung Cancer       Date:  2015-05-18       Impact factor: 5.705

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 5.  Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Authors:  Ignacio Melero; David M Berman; M Angela Aznar; Alan J Korman; José Luis Pérez Gracia; John Haanen
Journal:  Nat Rev Cancer       Date:  2015-08       Impact factor: 60.716

6.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

Authors:  R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

Review 7.  Fine tuning the immune response through B7-H3 and B7-H4.

Authors:  Kyung H Yi; Lieping Chen
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

8.  PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.

Authors:  Cécile Badoual; Stéphane Hans; Nathalie Merillon; Cordélia Van Ryswick; Patrice Ravel; Nadine Benhamouda; Emeline Levionnois; Mevyn Nizard; Ali Si-Mohamed; Nicolas Besnier; Alain Gey; Rinat Rotem-Yehudar; Hélène Pere; Thi Tran; Coralie L Guerin; Anne Chauvat; Estelle Dransart; Cécile Alanio; Sebastien Albert; Beatrix Barry; Federico Sandoval; Françoise Quintin-Colonna; Patrick Bruneval; Wolf H Fridman; Francois M Lemoine; Stephane Oudard; Ludger Johannes; Daniel Olive; Daniel Brasnu; Eric Tartour
Journal:  Cancer Res       Date:  2012-11-07       Impact factor: 12.701

9.  B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.

Authors:  Yixiang Mao; Wei Li; Kai Chen; Yufeng Xie; Qiang Liu; Min Yao; Weiming Duan; Xiumin Zhou; Rongrui Liang; Min Tao
Journal:  Oncotarget       Date:  2015-02-20

10.  B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma.

Authors:  Jinhua Wang; Kelly K Chong; Yoshitaka Nakamura; Linhda Nguyen; Sharon K Huang; Christine Kuo; Wang Zhang; Hua Yu; Donald L Morton; Dave S B Hoon
Journal:  J Invest Dermatol       Date:  2013-03-08       Impact factor: 8.551

View more
  72 in total

1.  Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.

Authors:  Katie M Leick; Joel Pinczewski; Ileana S Mauldin; Samuel J Young; Donna H Deacon; Amber N Woods; Marcus W Bosenberg; Victor H Engelhard; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2019-05-27       Impact factor: 6.968

2.  Melanoma subtypes demonstrate distinct PD-L1 expression profiles.

Authors:  Genevieve J Kaunitz; Tricia R Cottrell; Mohammed Lilo; Valliammai Muthappan; Jessica Esandrio; Sneha Berry; Haiying Xu; Aleksandra Ogurtsova; Robert A Anders; Alexander H Fischer; Stefan Kraft; Meg R Gerstenblith; Cheryl L Thompson; Kord Honda; Jonathan D Cuda; Charles G Eberhart; James T Handa; Evan J Lipson; Janis M Taube
Journal:  Lab Invest       Date:  2017-07-24       Impact factor: 5.662

Review 3.  Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-09       Impact factor: 3.875

4.  Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Authors:  Paolo A Ascierto; Sanjiv S Agarwala; Gennaro Ciliberto; Sandra Demaria; Reinhard Dummer; Connie P M Duong; Soldano Ferrone; Silvia C Formenti; Claus Garbe; Ruth Halaban; Samir Khleif; Jason J Luke; Lluis M Mir; Willem W Overwijk; Michael Postow; Igor Puzanov; Paul Sondel; Janis M Taube; Per Thor Straten; David F Stroncek; Jennifer A Wargo; Hassane Zarour; Magdalena Thurin
Journal:  J Transl Med       Date:  2017-11-16       Impact factor: 5.531

Review 5.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

6.  GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC.

Authors:  Chengzhong Lin; Wei Cao; Zhenhu Ren; Yu Tang; Chunye Zhang; Rong Yang; Yiming Chen; Zheqi Liu; Canbang Peng; Lizhen Wang; Xu Wang; Tong Ji
Journal:  Oncoimmunology       Date:  2017-07-20       Impact factor: 8.110

Review 7.  PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy.

Authors:  Tricia R Cottrell; Janis M Taube
Journal:  Cancer J       Date:  2018 Jan/Feb       Impact factor: 3.360

8.  Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.

Authors:  Denira Imamovic; Semir Vranic
Journal:  Ann Transl Med       Date:  2017-12

9.  The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Authors:  Shamaila Munir Ahmad; Evelina Martinenaite; Morten Holmström; Mia Aaboe Jørgensen; Özcan Met; Claudia Nastasi; Uffe Klausen; Marco Donia; Lars Møller Pedersen; Lars Munksgaard; Niels Ødum; Anders Woetmann; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2017-11-01       Impact factor: 8.110

10.  B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.

Authors:  Mehmet Altan; Vasiliki Pelekanou; Kurt A Schalper; Maria Toki; Patricia Gaule; Konstantinos Syrigos; Roy S Herbst; David L Rimm
Journal:  Clin Cancer Res       Date:  2017-05-24       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.